Eisai to Acquire MGI PHARMA for $41 Per Share in an All Cash Transaction

Eisai to Acquire MGI PHARMA for $41 Per Share in an All Cash Transaction

TOKYO & BLOOMINGTON, Minn.----Eisai Co., Ltd. , a research-based human health care company that focuses on neurology, gastrointestinal disorders, oncology and critical care, and MGI PHARMA, Inc. , an oncology and acute care focused biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI PHARMA for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.

BUSINESS WIRE